Phage therapy for multi-drug resistant respiratory tract infections

Joshua J. Iszatt, Alexander N. Larcombe, Hak Kim Chan, Stephen M. Stick, Luke W. Garratt, Anthony Kicic

Research output: Contribution to journalReview articlepeer-review

17 Citations (Scopus)


The emergence of multi-drug resistant (MDR) bacteria is recognised today as one of the greatest challenges to public health. As traditional antimicrobials are becoming ineffective and research into new antibiotics is diminishing, a number of alternative treatments for MDR bacteria have been receiving greater attention. Bacteriophage therapies are being revisited and present a promising opportunity to reduce the burden of bacterial infection in this post-antibiotic era. This review focuses on the current evidence supporting bacteriophage therapy against prevalent or emerging multi-drug resistant bacterial pathogens in respiratory medicine and the challenges ahead in preclinical data generation. Starting with efforts to improve delivery of bacteriophages to the lung surface, the current developments in animal models for relevant efficacy data on respiratory infections are discussed before finishing with a summary of findings from the select human trials performed to date.

Original languageEnglish
Article number1809
Issue number9
Publication statusPublished - Sept 2021


Dive into the research topics of 'Phage therapy for multi-drug resistant respiratory tract infections'. Together they form a unique fingerprint.

Cite this